DUBLIN–(BUSINESS WIRE)–The “Cluster Headache Syndrome (Cluster Headache) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Cluster Headache Syndrome – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic. (Read more…)
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Cluster Headache Syndrome (Cluster Headache) – Overview
Cluster Headache Syndrome (Cluster Headache) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Cluster Headache Syndrome (Cluster Headache) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Cluster Headache Syndrome (Cluster Headache) – Companies Involved in Therapeutics Development
- CCH Pharmaceuticals ApS
- Clexio Biosciences Ltd
- Crossject SA
- Eli Lilly and Co
- Mind Medicine Inc
- NeuroPharm Inc
- TrioxBio Inc
- Winston Pharmaceuticals Inc
- Zosano Pharma Corp
Cluster Headache Syndrome (Cluster Headache) – Drug Profiles
CLE-500 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
galcanezumab – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
ketamine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Cluster Headache Syndrome (Cluster Headache) – Dormant Projects
Cluster Headache Syndrome (Cluster Headache) – Discontinued Products
Cluster Headache Syndrome (Cluster Headache) – Product Development Milestones
- Featured News & Press Releases
- Jun 08, 2020: Phase 2 clinical trial of LSD for “Suicide Headaches” begins treating patients
- Feb 27, 2020: CHMP adopted a negative opinion for an extension of indication for Emgality
- Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
- Jun 05, 2019: FDA approves first drug for episodic cluster headaches
- May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio
- Mar 05, 2019: Lilly receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults
- Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache
- May 15, 2018: Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
- Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pvb540
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900